Form 4: Quanterix CTO Executes Routine RSU Vesting
Statement of Changes in Beneficial Ownership
Quanterix Corporation Chief Technology Officer Michael Miller acquired and sold shares to cover tax obligations related to RSU vesting.
Summary
- Chief Technology Officer Michael Miller acquired 1,558 shares of common stock through the vesting of restricted stock units (RSUs).
- A total of 464 shares were withheld by the company to satisfy tax withholding obligations at a price of $2.75 per share.
- The net increase in beneficial ownership for the reporting person was 1,094 shares.
- The transactions occurred on May 15, 2026, pursuant to pre-existing equity compensation plans.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents routine administrative activity related to executive compensation rather than a strategic shift or market-moving event.
Positives
- The transaction reflects standard equity compensation vesting for a key executive.
- The executive maintains a significant beneficial ownership position of 33,704 shares following the transaction.
Negatives
- The sale of shares to cover tax obligations is a standard administrative process and does not reflect a change in executive sentiment.
Risks
- The company is subject to standard market risks associated with the biotechnology and life sciences sector.
- Reliance on key personnel, including the Chief Technology Officer, for ongoing innovation and product development.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a routine disclosure of executive equity transactions.
Management Comments
- No specific management commentary was provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that this filing is a standard administrative disclosure common in the biotechnology sector, where equity-based compensation is a primary tool for executive retention and alignment with shareholder interests.
Comparison to Industry Standards
- The vesting schedule and tax-withholding mechanism are consistent with standard corporate governance practices for U.S. publicly traded life sciences companies.
- The use of Rule 10b5-1 style tax withholding is standard practice among peers such as Illumina or Pacific Biosciences.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Michael Miller granted Power of Attorney to Daniel Char, Michael Lanieri, Bonnie McManus, and Meghan Shevlin for SEC filing purposes. | 02/17/2026 | Administrative change to facilitate timely regulatory compliance. |
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a routine equity compensation event.
Next Steps
- Continued monitoring of future Form 4 filings for any changes in executive ownership stakes.
Key Dates
| Date | Description |
|---|---|
| 02/06/2023 | Initial grant date for the first batch of RSUs. |
| 03/15/2023 | Initial grant date for the second batch of RSUs. |
| 02/02/2024 | Initial grant date for the third batch of RSUs. |
| 05/21/2024 | Initial grant date for the fourth batch of RSUs. |
| 02/04/2025 | Initial grant date for the fifth batch of RSUs. |
| 02/17/2026 | Execution date of the Power of Attorney for the reporting person. |
| 05/15/2026 | Date of the reported RSU vesting and tax withholding transactions. |
| 05/18/2026 | Date of the SEC filing submission. |
Keywords
Quanterix, QTRX, Insider Trading, Form 4, Biotechnology, Equity Compensation, Executive Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.